Generally, GLP-1 agonist medications are FDA approved for adults aged 18 years and older with certain body mass indexes (BMI) (typically a BMI of 30 or above, or a BMI of 27 or above if you have a weight-related health condition such as hypertension, high cholesterol, weight-related anxiety, liver disease, sleep apnea or PCOS)
OptumRx PA criteria for Zepbound Standard OptumRx PA for Zepbound (obesity indication) typically requires: BMI 30 or higher, or BMI 27 with documented comorbidity (hypertension, type 2 diabetes, dyslipidemia, OSA) Participation in a structured weight-management program, typically 3 to 6 months of documented engagement Absence of contraindications (personal or family history of MTC, MEN 2) Attestation of medical necessity by the prescribing physician For step-therapy plans, prior trial of preferred GLP-1 alternative Initial approval is generally 6 months, with reauthorization requiring documented weight loss of 5% or more from baseline
Neutrophil-to-lymphocyte ratio and lymphocyte count reflect alterations in central neurodegeneration-associated proteins and clinical severity in Parkinson disease patients
While foods like avocados, spinach, and garlic contain glutathione or its precursors, the body does not absorb dietary glutathione very efficiently
Some studies have reported that knockdown of GLP-1R in Sim1 neurons did not affect body weight, body composition, or food intake, nor did it significantly change the anorexic effects induced by i.p
They are not statements about human outcomes
